Characteristics and clinical outcomes of patients with cardiogenic shock complicating acute myocardial infarction treated by emergent coronary angioplasty

References

• Goldberg R. J., Samad N. A., Yarzebski J., Gurwitz J., Bigelow C., Gore J. M. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med 1999; 340: 1162–8
   PubMed Web of Science ®Google Scholar
• Carnendran L., Abboud R., Sleeper L. A., et al. Trends in cardiogenic shock: report from the SHOCK study. Eur Heart J 2001; 22: 472–8
   PubMed Web of Science ®Google Scholar
• Holmes D. R., Jr, Bates E. R., Kleiman N. S., et al. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO‐I trial experience. The GUSTO‐I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1995; 26: 668–74
   PubMed Web of Science ®Google Scholar
• Ashby D. T., Stone G. W., Moses J. W. Cardiogenic shock in acute myocardial infarction. Catheter Cardiovasc Interv 2003; 59: 34–43
   PubMed Web of Science ®Google Scholar
• Giri S., Mitchel J., Azar R. R., et al. Results of primary percutaneous transluminal coronary angioplasty plus abciximab with or without stenting for acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol 2002; 89: 126–31
   PubMed Web of Science ®Google Scholar
• Chan A. W., Chew D. P., Bhatt D. L., Moliterno D. J., Topol E. J., Ellis S. G. Long‐term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction. Am J Cardiol 2002; 89: 132–6
   PubMed Web of Science ®Google Scholar
• Antoniucci D., Valenti R., Migliorini A., et al. Abciximab therapy improves survival in patients with acute myocardial infarction complicated by early cardiogenic shock undergoing coronary artery stent implantation. Am J Cardiol 2002; 90: 353–7
   PubMed Web of Science ®Google Scholar
• Hasdai D., Harrington R. A., Hochman J. S., et al. Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST‐segment elevation. J Am Coll Cardiol 2000; 36: 685–92
   PubMed Web of Science ®Google Scholar
• Huang R., Sacks J., Thai H., et al. Impact of stents and abciximab on survival from cardiogenic shock treated with percutaneous coronary intervention. Catheter Cardiovasc Interv 2005; 65: 25–33
   PubMed Web of Science ®Google Scholar
• Antman E. M., Anbe D. T., Armstrong P. W., et al. ACC/AHA guidelines for the management of patients with ST‐elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 2004; 44: E1–E211
   PubMedGoogle Scholar
• Iakobishvili Z., Behar S., Boyko V., Battler A., Hasdai D. Does current treatment of cardiogenic shock complicating the acute coronary syndromes comply with guidelines?. Am Heart J 2005; 149: 98–103
   PubMed Web of Science ®Google Scholar
• Dauerman H., Goldberg R. J., White K., et al. Revascularization, stenting, and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol 2002; 90: 838–42
   PubMed Web of Science ®Google Scholar
• Hochman J. S., Sleeper L. A., Webb J. G., et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med 1999; 341: 625–34
   PubMed Web of Science ®Google Scholar
• Sanborn T. A., Sleeper L. A., Bates E. R., et al. Impact of thrombolysis, intra‐aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. J Am Coll Cardiol 2000; 36: 1123–9
   PubMed Web of Science ®Google Scholar
• Rogers W. J., Canto J. G., Lambrew C. T., et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999:the National registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol 2000; 36: 2056–66
   PubMed Web of Science ®Google Scholar
• Zeymer U., Tebbe U., Weber M., et al. Prospective Evaluation of Early Abciximab and Primary Percutaneous Intervention for Patients with ST elevation Myocardial Infarction Complicated by Cardiogenic Shock: Results of the REOSHOCK Trial. J Invasive Cardiol 2003; 15: 385–9
   PubMedGoogle Scholar
• Karcz M., Bekta P., Kepka C. et al. Acute myocardial infarction complicated by cardiogenic shock. In‐hospital and mid‐term results of invasive treatment in the National Institute of Cardiology, Warsaw‐Anin. Kardiol Pol 2003; 58: 366–74
   PubMedGoogle Scholar
• Dzavik V., Sleeper L. A., Picard M. H., et al. Should we emergently revascularize Occluded Coronaries in cardiogenic shock Investigators. Outcome of patients aged > or = 75 years in the should we emergently revascularize Occluded Coronaries in cardiogenic shock (SHOCK) trial: do elderly patients with acute myocardial infarction complicated by cardiogenic shock respond differently to emergent revascularization?. Am Heart J 2005; 149: 1128–34
   PubMed Web of Science ®Google Scholar